PHILADELPHIA and Vancouver, British Columbia, Dec. 11, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the pricing of an underwritten public offering of 7,400,000 common shares and warrants to purchase 7,400,000 common shares…
Thu, 03 Apr 2025 22:54:00 GMT BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report)’s share price was up 4% during trading on Thursday . The company traded as high as $3.69 and last traded at $3.61. Approximately 25,206 ...
Wed, 26 Mar 2025 01:00:00 GMT PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage ...
Tue, 25 Mar 2025 22:01:00 GMT Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/. About BriaCell Therapeutics Corp. BriaCell ...
Thu, 20 Mar 2025 05:06:00 GMT Therapeutics announces that the external Data Safety Monitoring Board, an independent group of experts who review and monitor ...